Why Does C. Diff Keep Coming Back? Recurrent Pseudomembranous Colitis, Treatment, and Prevention

Finishing treatment for a Clostridioides difficile infection can feel like reaching the end of a long and exhausting illness. The diarrhea settles, abdominal pain eases, appetite begins to return, and life slowly starts to feel normal again. Then, sometimes within a few weeks, the symptoms come back.

This return of diarrhea and colitis is known as recurrent Clostridioides difficile infection. When the inflammation is severe enough to produce raised yellow-white plaques along the lining of the colon, it may be described as pseudomembranous colitis. However, not every recurrent infection causes visible pseudomembranes, and a colonoscopy is not usually required to confirm recurrence.

According to the Centers for Disease Control and Prevention, approximately 1 in 9 people treated for Clostridioides difficile infection experience another episode within the following two to eight weeks. ^[1] Other clinical sources estimate recurrence in approximately 10% to 20% of treated cases, with the likelihood rising substantially after the first recurrence. ^[2]

The infection often returns not because a person did something wrong, but because the bacterium is unusually difficult to eliminate and the intestinal microbiome may remain vulnerable long after the initial diarrhea improves. Understanding why this happens is essential because recurrent pseudomembranous colitis often requires a different treatment strategy from the first infection.

Clostridioides difficile is a bacterium that can live in the intestine and produce toxins capable of damaging the colon. It commonly becomes a problem after antibiotics disturb the normal community of protective bacteria in the digestive tract.

Without enough protective bacteria, Clostridioides difficile can multiply and release toxins. These toxins injure the intestinal lining, causing inflammation, watery diarrhea, abdominal cramping, fever, nausea, reduced appetite, and sometimes blood or mucus in the stool. ^[3]

Pseudomembranous colitis is a particularly recognizable form of this inflammation. The “pseudomembranes” are patches made from inflammatory cells, mucus, fibrin, and damaged tissue. They may be seen during colonoscopy, but colonoscopy is generally reserved for situations in which the diagnosis is unclear, stool testing cannot be obtained, or another form of colitis is suspected.

A recurrent infection usually means that symptoms return after they had initially improved or resolved following appropriate treatment. Most recurrences appear within two to eight weeks, although a new episode can occasionally occur later, particularly after another course of antibiotics or a new exposure to Clostridioides difficile spores. ^[1]

Recurrent Clostridioides difficile infection is not always caused by failure of the medication. In many cases, the antibiotic successfully kills the actively growing bacteria and stops toxin production. The problem is that several conditions that allowed the original infection to develop may still be present.

One of the main reasons Clostridioides difficile keeps coming back is its ability to form spores.

Spores are dormant, highly resistant forms of the bacterium. They can survive many antibiotics, ordinary household cleaning products, alcohol-based hand sanitizers, stomach acid, and long periods on environmental surfaces. Antibiotics such as vancomycin and fidaxomicin mainly act against actively growing bacteria. They do not reliably destroy every dormant spore.

After treatment ends, surviving spores may become active again. If the normal intestinal bacteria have not recovered enough to control them, Clostridioides difficile can multiply and begin producing toxins once more.

The colon normally contains a complex community of bacteria that helps prevent harmful organisms from taking over. These protective bacteria compete for nutrients, influence immune function, produce beneficial compounds, and transform bile acids in ways that make the intestinal environment less favorable for Clostridioides difficile.

Broad-spectrum antibiotics can severely disrupt this microbial ecosystem. Unfortunately, the antibiotics used to treat Clostridioides difficile infection may also delay complete microbiome recovery, although some treatments are more selective than others.

This creates a difficult cycle: antibiotics suppress Clostridioides difficile, but the intestine may remain biologically vulnerable after treatment. When the antibiotic is stopped, the bacterium can regain its foothold before protective organisms return in sufficient numbers. ^[4]

Some patients need additional antibiotics soon after recovering from Clostridioides difficile infection. They may develop a urinary tract infection, pneumonia, dental infection, skin infection, or another medical problem requiring treatment.

A new antibiotic can disturb the intestinal microbiome again, even when it is prescribed for an infection elsewhere in the body. Broad-spectrum antibiotics and prolonged courses are especially concerning, although virtually any antibiotic can contribute to risk.

This does not mean that a medically necessary antibiotic should be refused. Instead, every prescriber should know about the previous Clostridioides difficile infection so the narrowest effective antibiotic can be selected for the shortest appropriate period.

The immune system produces antibodies against the toxins released by Clostridioides difficile. Some people develop a stronger protective immune response than others.

Older adults, people receiving immune-suppressing medications, cancer patients, transplant recipients, and people with serious chronic illnesses may have greater difficulty developing or maintaining sufficient protection. This can make another episode more likely even after the original infection was treated correctly.

Not every recurrence is caused by the original bacterial strain. A person can also be exposed to Clostridioides difficile again.

The spores can remain on toilets, bathroom fixtures, bed linens, clothing, medical equipment, doorknobs, mobility aids, and other frequently touched surfaces. They are especially common in hospitals, rehabilitation facilities, and nursing homes, although community exposure is also possible.

Because the intestinal microbiome remains fragile after treatment, a relatively small exposure may be more consequential during the recovery period.

Anyone who has had Clostridioides difficile infection can experience recurrence, but the risk is not equal for everyone.

The likelihood is generally higher among people who:

• Are 65 years of age or older
• Have already had one or more recurrences
• Required hospitalization for the original infection
• Had severe colitis, kidney dysfunction, or a high white blood cell count
• Are receiving chemotherapy or immune-suppressing treatment
• Have inflammatory bowel disease
• Need additional antibiotics during or soon after treatment
• Have significant chronic kidney, liver, or cardiovascular disease
• Live in or frequently visit healthcare facilities
• Have had recent gastrointestinal surgery
• Require ongoing medications that alter normal intestinal conditions

The risk becomes progressively greater after each recurrence. The American College of Gastroenterology notes that after one recurrence, the chance of additional episodes may rise to approximately 40% to 60%. ^[2]

This increasing risk is why treatment often shifts from simply suppressing the bacterium to actively restoring resistance within the intestinal microbiome.

No. This is one of the most important points for patients recovering from pseudomembranous colitis.

The intestine may remain sensitive for weeks or months after a serious infection. Temporary food intolerance, altered bowel motility, medication side effects, lactose intolerance, anxiety-related bowel changes, and post-infectious irritable bowel syndrome can all cause loose stools, gas, urgency, cramping, or irregular bowel movements.

Research suggests that post-infectious irritable bowel syndrome is relatively common after Clostridioides difficile infection. ^[5] These symptoms may resemble a recurrence, but repeatedly treating noninfectious diarrhea with antibiotics can further damage the microbiome.

A true recurrence is more concerning when there is a return of frequent watery diarrhea, particularly three or more unformed stools in 24 hours, together with increasing urgency, abdominal pain, fever, nausea, weakness, dehydration, or a recent antibiotic exposure.

Symptoms alone cannot always distinguish recurrence from post-infectious bowel dysfunction. Stool testing and clinical assessment are usually needed before another course of treatment is started.

Diagnosis should begin with symptoms. Testing is generally intended for people who have new, unexplained diarrhea rather than people whose stools are formed or whose symptoms have completely resolved.

Laboratories may use toxin tests, molecular tests that detect toxin-producing genes, or multistep testing strategies. Molecular tests are highly sensitive, but they can remain positive in people who carry Clostridioides difficile without having active toxin-mediated disease. ^[6]

For this reason, a positive molecular result does not automatically prove that every episode of loose stool is recurrent infection. The result must be interpreted together with stool frequency, medication use, recent laxative exposure, abdominal symptoms, and overall clinical condition.

Repeat testing after successful treatment is not recommended as a “test of cure.” A person may continue carrying the bacterium or its genetic material even when the infection is no longer active. Testing is more useful when compatible symptoms return. ^[6]

Blood tests may be ordered to evaluate dehydration, kidney function, electrolyte abnormalities, inflammation, and white blood cell count. Abdominal imaging may be needed when severe colitis, bowel dilation, perforation, or toxic megacolon is suspected.

Treatment depends on which recurrence has occurred, what medication was used previously, whether the infection is severe, and the patient’s risk of another episode.

Treatment should be selected by a healthcare professional. Patients should not restart leftover vancomycin, use another person’s medication, or rely on antidiarrheal drugs without medical advice.

Current Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidance favors fidaxomicin over a standard course of vancomycin for recurrent, non-fulminant Clostridioides difficile infection when fidaxomicin is available and appropriate. ^[7]

Fidaxomicin is relatively selective in its antibacterial activity and generally causes less disruption of some protective intestinal bacteria than broader antibiotic treatments. It may be prescribed as a standard course or, in selected patients, as an extended-pulsed regimen.

Its main limitation is often cost or insurance coverage. When fidaxomicin is not accessible, other effective options remain available.

Oral vancomycin remains an important treatment for recurrent pseudomembranous colitis.

Instead of stopping the medication after a standard course, the physician may gradually reduce the dose and then administer it at increasingly spaced intervals. This is known as a vancomycin taper-and-pulse regimen.

The reasoning is practical: vancomycin suppresses active bacteria, while the medication-free intervals may allow dormant spores to become active. The next scheduled dose can then target those newly active organisms.

The exact regimen can extend over several weeks and must be followed carefully. Patients should not design or modify a taper themselves.

For people with multiple recurrences, another option described in clinical guidelines is a standard course of oral vancomycin followed by rifaximin.

This approach is sometimes called a rifaximin “chaser.” It is not suitable for every patient, and concerns such as resistance, previous treatment history, medication availability, and individual health conditions must be considered.

Antibiotics control active infection, but they do not necessarily rebuild the intestinal ecosystem. Microbiota-based therapies are intended to restore some of the organisms and functions that help prevent Clostridioides difficile from returning.

The American Gastroenterological Association recommends considering fecal microbiota-based therapies after standard antibiotic treatment in selected adults with recurrent infection, particularly those who are not severely immunocompromised. ^[8]

These treatments are generally given after the active episode has been brought under control with antibiotics. They are not substitutes for emergency treatment of uncontrolled severe or fulminant colitis.

Fecal microbiota transplantation involves transferring carefully screened and processed donor microbiota into the patient’s intestinal tract. It may be delivered through colonoscopy, an intestinal tube, an enema preparation, or specially manufactured oral products, depending on the treatment used.

The goal is not simply to add “good bacteria.” It is to restore a functioning microbial community capable of resisting Clostridioides difficile growth, supporting healthy bile acid metabolism, and reducing the bacterium’s opportunity to produce toxins.

Conventional fecal microbiota transplantation should only be performed through qualified medical services using rigorous donor screening. At-home or do-it-yourself fecal transplantation is unsafe because unscreened stool can transmit harmful bacteria, parasites, viruses, or organisms carrying antibiotic-resistance genes.

Rebyota is a United States Food and Drug Administration-approved fecal microbiota product administered rectally. It is indicated for adults following antibiotic treatment for recurrent Clostridioides difficile infection. ^[9]

It is used to prevent another recurrence rather than to treat an active, uncontrolled infection. The clinician determines when the antibiotic course should end and when the microbiota product should be administered.

Vowst is an oral fecal microbiota spore product approved for adults after antibacterial treatment for recurrent Clostridioides difficile infection. ^[10]

It provides a capsule-based option for microbiome restoration. As with Rebyota, it is intended to reduce the likelihood of another episode after the active infection has been treated.

Patients receiving microbiota-based products need careful timing instructions because additional antibiotics given around the treatment period may interfere with microbiome restoration.

Bezlotoxumab is a monoclonal antibody that binds to and neutralizes Clostridioides difficile toxin B. Earlier clinical guidelines recommended considering it alongside antibiotics for selected patients at high risk of recurrence. ^[7]

However, the manufacturer discontinued the United States product, sold as Zinplava, effective January 31, 2025. Availability may differ by country, and patients should ask their treating clinician whether it remains accessible in their region. ^[11]

Bezlotoxumab was never a replacement for antibiotics because it did not eliminate the bacterium. Its purpose was to reduce the risk of another toxin-mediated episode.

No prevention plan can guarantee that Clostridioides difficile will never return. Nevertheless, several steps can meaningfully reduce avoidable risk.

Every doctor, dentist, urgent care clinician, and hospital team should be informed about the history of recurrent Clostridioides difficile infection.

When antibiotics are genuinely necessary, the prescriber may be able to select a narrower treatment, shorten the duration, or avoid antibiotics associated with greater intestinal disruption. Antibiotics should not be skipped when they are needed for a serious bacterial infection, but they should not be used for viral illnesses or vague symptoms without a clear indication.

Recent American Gastroenterological Association expert guidance specifically advises people with a history of Clostridioides difficile infection to avoid unnecessary antibiotic therapy. ^[12]

Proton pump inhibitors and other acid-suppressing medicines are medically necessary for many people with conditions such as severe gastroesophageal reflux disease, erosive esophagitis, ulcer prevention, or gastrointestinal bleeding risk.

Patients should not stop these medications without medical advice. However, the reason for continued treatment should be reviewed. If there is no longer a valid indication, reducing unnecessary medication exposure may be appropriate. If a legitimate indication remains, expert guidance does not recommend automatic discontinuation solely because of a previous Clostridioides difficile infection. ^[12]

Alcohol-based hand sanitizer does not reliably remove or kill Clostridioides difficile spores. Washing with soap and water is more effective at physically removing spores from the hands.

Handwashing is especially important after using the bathroom, before preparing food, before eating, after handling soiled laundry, and after assisting someone with toileting. ^[13]

During active diarrhea and the early recovery period, clean frequently touched surfaces such as toilet seats, toilet handles, sink taps, bathroom doorknobs, shower handles, and light switches.

The Centers for Disease Control and Prevention advises using a product effective against Clostridioides difficile spores. Chlorine bleach may be appropriate for compatible household surfaces when used according to label directions. Cleaning should occur before disinfection when surfaces are visibly soiled. ^[13]

Do not mix bleach with ammonia, acids, or other cleaning agents because dangerous gases can form.

Wash soiled underwear, towels, bedding, and clothing promptly. Use the hottest water that is safe for the fabric and dry items thoroughly.

Avoid shaking contaminated laundry because this can spread material into the surrounding environment. Wash your hands with soap and water after handling soiled items.

During active infection, the affected person should use a separate towel whenever possible. Bathroom surfaces should be cleaned regularly, particularly when the bathroom is shared.

Complete isolation at home is usually unnecessary once diarrhea has stopped and hygiene can be maintained, but careful handwashing should continue.

There is no specific diet proven to eliminate Clostridioides difficile spores or guarantee that the infection will not return.

During active diarrhea, hydration is the immediate priority. Water, oral rehydration fluids, soups, and other tolerated liquids may help replace lost fluid and electrolytes. Severe dehydration requires medical care.

As recovery progresses, a balanced diet with a variety of plant foods may support general microbiome recovery. Recent expert guidance encourages a healthy diet containing different fruits, vegetables, and sources of soluble and insoluble fiber when tolerated. ^[12]

Fiber should be increased gradually. A person recovering from colitis may temporarily experience bloating, cramping, urgency, or intolerance to high-fiber foods. There is no need to force large amounts of raw vegetables or bran during active gastrointestinal symptoms.

Fermented foods and yogurt may be tolerated by some people, but food cannot replace prescribed treatment or medically supervised microbiota therapy.

Probiotics are frequently marketed for antibiotic-associated diarrhea, but evidence for preventing recurrent Clostridioides difficile infection remains inconsistent.

Different probiotic products contain different organisms, doses, and manufacturing standards, making the results difficult to generalize. Recent American Gastroenterological Association expert advice does not recommend probiotics for preventing either an initial or recurrent Clostridioides difficile infection. ^[12]

Probiotics may also pose risks for critically ill or severely immunocompromised people. Patients should discuss them with a clinician rather than assuming that any over-the-counter product is harmless or effective.

Clostridioides difficile infection can progress rapidly. Urgent medical evaluation is needed for:

• Frequent or rapidly worsening watery diarrhea
• Inability to keep fluids down
• Signs of dehydration, including dizziness or very little urine
• Severe or increasing abdominal pain
• Significant abdominal swelling or firmness
• High fever
• Confusion, fainting, or extreme weakness
• Rapid heartbeat or low blood pressure
• Blood in the stool
• Reduced bowel movements despite increasing pain and abdominal swelling

A sudden decrease in diarrhea is not always reassuring when severe pain and swelling are developing. In fulminant colitis, the colon may stop moving normally, resulting in ileus or toxic megacolon.

Severe or fulminant Clostridioides difficile infection may require hospitalization, intravenous fluids, high-dose oral or tube-administered vancomycin, intravenous metronidazole, surgical consultation, and intensive monitoring. Rebyota and Vowst are not approved as treatments for active severe or fulminant infection. ^[12]

Yes. Many people eventually break the recurrence cycle, including those who have experienced several episodes.

The key is recognizing that repeated recurrence is not always solved by simply repeating the same short antibiotic course. Treatment may need to address both parts of the problem: controlling active Clostridioides difficile and restoring the intestinal environment that prevents it from returning.

Fidaxomicin, tapered and pulsed vancomycin regimens, selected antibiotic combinations, conventional fecal microbiota transplantation, and approved microbiota-based products have substantially expanded the treatment options available.

Recovery of normal bowel function may take longer than eradication of active infection. Intermittent loose stools, food sensitivity, gas, or urgency do not automatically mean that Clostridioides difficile has returned. At the same time, persistent or worsening watery diarrhea should never be ignored.

The safest approach is to report returning symptoms promptly, obtain appropriate testing when indicated, avoid unnecessary antibiotics, and discuss recurrence-prevention treatment before another episode develops.

Recurrence most commonly develops within two to eight weeks after treatment ends. Symptoms can return sooner, and a new infection can also occur months later, particularly following another antibiotic exposure.

Symptoms can persist or worsen during treatment if the infection is severe, the medication is not reaching the colon adequately, another illness is causing diarrhea, or complications are developing. Medical reassessment is necessary rather than simply extending treatment without supervision.

A person with active diarrhea can shed large numbers of spores. People may also continue carrying and spreading spores after symptoms improve. Soap-and-water handwashing and appropriate bathroom cleaning remain important during recovery. ^[1]

Routine testing of household members without symptoms is not generally recommended. A positive test in someone without diarrhea may indicate colonization rather than active disease.

Stress does not directly reactivate Clostridioides difficile spores in the way antibiotics can disrupt the microbiome. However, stress can alter bowel habits and intensify post-infectious irritable bowel symptoms, which may feel similar to recurrence.

No. Antibiotics may be lifesaving and should be used when medically necessary. The goal is to avoid unnecessary treatment and choose the most targeted effective option after considering the person’s recurrence risk.

References: